<DOC>
	<DOCNO>NCT00615667</DOCNO>
	<brief_summary>Exploring efficacy safety Tacrolimus refractory nephrotic syndrome ; Acquiring experience Tacrolimus treatment refractory nephrotic syndrome Chinese patient .</brief_summary>
	<brief_title>Prospective , Multicenter Study Efficacy Tolerance Tacrolimus Refractory Nephrotic Syndrome ( RNS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Subjects either sex , 1465 year age ; 2 . Diagnosis Nephrotic syndrome hypoalbuminemia ( &lt; 3.0g/dl ) heavy proteinuria ( &gt; 3.5g/24hr ) ; 3 . Provision write informed consent subject guardian ; 4 . Refractory nephrotic syndrome : Steroid resistant : Persistence proteinuria despite prednisone therapy 1mg/kg/d 16 week ; Steroid dependent : NS recur steroid dosage decease.Twice within 6 month , 3 time within 1 year . 1 . Inability unwillingness provide write informed consent ; 2 . Known hypersensitivity contraindication tacrolimus , cyclophosphamide , azathioprine , corticosteroid ; 3 . Usage immunosuppression therapy ( MMF , CTX , CysA , MTX ect ) 1 week within 1 month prior first randomization ; 4 . Pregnancy , nursing use nonreliable method contraception ; 5 . Continuous dialysis start 2 week randomization induction phase and/or continuous dialysis anticipate duration 8 week ; 6 . Previous kidney transplant plant transplant ; 7 . Scr &gt; 4mg/dl ( 353umol/L ) ; 8 . Active hepatitis , liver dysfunction ; 9 . Diagnosed DM ; 10 . Participation another clinic trial and/or receipt investigational drug within 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Refractory Nephrotic syndrome</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>